# **SUPPLEMENTARY TABLE 4** Univariate analysis examining association between baseline clinico-pathological factors and PSA response in patients switched onto enzalutamide after collection of circulating cell-free DNA (*n* = 39)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable**  | ***n*** | **PSA50 %** | ***P***  | **PSA30 %** | ***P***  |
| AR copy number increase ± AR exon 8 mutation in cfDNA Yes No | 1920 | 2150 | 0.06 | 2160 | **0.013** |
| AR copy number increase in cfDNA Yes  No | 1425 | 2144 | 0.16 | 2152 | 0.06 |
| Prior docetaxel  Yes No | 1821 | 3338 | 0.76 | 3348 | 0.37 |
| Gleason score ≤ 7 8-10 | 1323 | 3135 | 1.00 | 3143 | 0.45 |
| ECOG performance status  0-1  ≥ 2 | 2811 | 4318 | 0.27 | 5018 | 0.09 |
| Visceral metastases Absent Present | 336 | 3917 | 0.40 | 4517 | 0.37 |
| Serum LDH (IU/L) > 250 ≤ 250 | 1821 | 2438 | 0.39 | 3348 | 0.37 |
| Serum ALP (IU/L)> 160 ≤ 160 | 1920 | 2145 | 0.16 | 2155 | 0.07 |
| Circulating tumor cells ≥ 5 < 5 | 1818 | 2250 | 0.08 | 2856 | 0.09 |
| No. lines systemic treatment^ ≥ 3 ≤ 2 | 2514 | 3636 | 0.51 | 4436 | 0.61 |
| DNA concentration (ng/µL) (continuous) | 39 | NA | 0.23 | NA | 0.14 |
| Hemoglobin (continuous) | 39 | NA | 0.22 | NA | 0.22 |

Association between variables and PSA response was examined using either Χ2 for categorical variables or logistic regression for continuous variables.

PSA50: PSA decline ≥ 50% maintained for ≥ 3 weeks

PSA30: PSA decline ≥ 30% maintained for ≥ 3 weeks

AR: Androgen receptor

ECOG: Eastern Co-operative group

LDH: Lactate dehydrogenase

ALP: Alkaline phosphatase

Circulating tumor cells: per 7.5 ml blood

^: Number of lines of systemic treatment beyond initial androgen deprivation therapy (LHRH agonist/antagonist)